Kevin DeGeeter
Stock Analyst at Ladenburg Thalmann
(2.86)
# 1,584
Out of 5,127 analysts
46
Total ratings
40%
Success rate
53.86%
Average return
Main Sectors:
Stocks Rated by Kevin DeGeeter
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DCOY Decoy Therapeutics | Initiates: Buy | $2.5 | $0.77 | +224.68% | 1 | Jan 23, 2026 | |
| NXTC NextCure | Upgrades: Buy | $18 | $11.76 | +53.06% | 1 | Nov 7, 2025 | |
| ORIC ORIC Pharmaceuticals | Initiates: Buy | $15 | $10.71 | +40.06% | 2 | Jul 8, 2025 | |
| CRDF Cardiff Oncology | Initiates: Buy | $19 | $1.58 | +1,102.53% | 1 | Jul 8, 2025 | |
| NVCR NovoCure | Initiates: Buy | $30 | $10.03 | +199.10% | 4 | Jul 8, 2025 | |
| ANTX AN2 Therapeutics | Initiates: Outperform | $22 | $1.08 | +1,937.04% | 1 | Apr 19, 2022 | |
| PSNL Personalis | Maintains: Outperform | $30 → $24 | $7.83 | +206.51% | 4 | Feb 25, 2022 | |
| FLGT Fulgent Genetics | Maintains: Outperform | $141 → $125 | $22.95 | +444.66% | 3 | Jan 25, 2022 | |
| MDXH MDxHealth | Initiates: Outperform | $18 | $3.66 | +391.80% | 1 | Nov 29, 2021 | |
| SERA Sera Prognostics | Initiates: Outperform | $19 | $2.65 | +616.98% | 1 | Nov 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $2.36 | - | 1 | Oct 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $79 | $166.00 | -52.31% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $161 → $155 | $103.32 | +50.02% | 2 | Jul 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $8.83 | - | 2 | Jun 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $3.13 | +698.72% | 1 | May 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $1,800 | $3.48 | +51,624.14% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $35.44 | - | 2 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $4.61 | - | 1 | Jan 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $3.20 | - | 4 | Dec 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $1,500 | $3.21 | +46,628.97% | 1 | Jul 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $1.15 | +78,160.87% | 1 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $8.70 | - | 2 | Aug 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $165 | $9.45 | +1,646.03% | 1 | Jun 6, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $5.07 | - | 5 | Feb 8, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $1.29 | - | 2 | Jan 4, 2017 |
Decoy Therapeutics
Jan 23, 2026
Initiates: Buy
Price Target: $2.5
Current: $0.77
Upside: +224.68%
NextCure
Nov 7, 2025
Upgrades: Buy
Price Target: $18
Current: $11.76
Upside: +53.06%
ORIC Pharmaceuticals
Jul 8, 2025
Initiates: Buy
Price Target: $15
Current: $10.71
Upside: +40.06%
Cardiff Oncology
Jul 8, 2025
Initiates: Buy
Price Target: $19
Current: $1.58
Upside: +1,102.53%
NovoCure
Jul 8, 2025
Initiates: Buy
Price Target: $30
Current: $10.03
Upside: +199.10%
AN2 Therapeutics
Apr 19, 2022
Initiates: Outperform
Price Target: $22
Current: $1.08
Upside: +1,937.04%
Personalis
Feb 25, 2022
Maintains: Outperform
Price Target: $30 → $24
Current: $7.83
Upside: +206.51%
Fulgent Genetics
Jan 25, 2022
Maintains: Outperform
Price Target: $141 → $125
Current: $22.95
Upside: +444.66%
MDxHealth
Nov 29, 2021
Initiates: Outperform
Price Target: $18
Current: $3.66
Upside: +391.80%
Sera Prognostics
Nov 19, 2021
Initiates: Outperform
Price Target: $19
Current: $2.65
Upside: +616.98%
Oct 1, 2021
Downgrades: Perform
Price Target: n/a
Current: $2.36
Upside: -
Aug 24, 2021
Maintains: Outperform
Price Target: $75 → $79
Current: $166.00
Upside: -52.31%
Jul 29, 2021
Maintains: Outperform
Price Target: $161 → $155
Current: $103.32
Upside: +50.02%
Jun 29, 2021
Downgrades: Perform
Price Target: n/a
Current: $8.83
Upside: -
May 27, 2021
Initiates: Outperform
Price Target: $25
Current: $3.13
Upside: +698.72%
Mar 2, 2021
Initiates: Outperform
Price Target: $1,800
Current: $3.48
Upside: +51,624.14%
Jan 11, 2021
Downgrades: Perform
Price Target: n/a
Current: $35.44
Upside: -
Jan 5, 2021
Initiates: Outperform
Price Target: n/a
Current: $4.61
Upside: -
Dec 8, 2020
Downgrades: Perform
Price Target: n/a
Current: $3.20
Upside: -
Jul 1, 2020
Initiates: Outperform
Price Target: $1,500
Current: $3.21
Upside: +46,628.97%
Apr 8, 2020
Initiates: Outperform
Price Target: $900
Current: $1.15
Upside: +78,160.87%
Aug 9, 2017
Upgrades: Buy
Price Target: n/a
Current: $8.70
Upside: -
Jun 6, 2017
Initiates: Buy
Price Target: $165
Current: $9.45
Upside: +1,646.03%
Feb 8, 2017
Upgrades: Neutral
Price Target: n/a
Current: $5.07
Upside: -
Jan 4, 2017
Upgrades: Buy
Price Target: n/a
Current: $1.29
Upside: -